SOHO 2025 | Aiming to further improve the outcomes of patients with CML
In this video, Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, briefly comments on strategies and efforts that may improve the outcomes of patients with chronic myeloid leukemia (CML). This includes combination approaches and the targeting of novel pathways to eliminate CML cells and increase the duration of treatment-free remission. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the development of new drugs is very exciting and yes we have a lot of TKIs already, we have six approved in the US, but there’s still gaps, you know, some of these drugs may be a little bit too toxic or the schedule is inconvenient or things like that where we still could improve on those areas. We can also look at ways of combining and there’s more and more efforts of combining drugs for example a myristoyl pocket inhibitor with a traditional inhibitor...
I think that the development of new drugs is very exciting and yes we have a lot of TKIs already, we have six approved in the US, but there’s still gaps, you know, some of these drugs may be a little bit too toxic or the schedule is inconvenient or things like that where we still could improve on those areas. We can also look at ways of combining and there’s more and more efforts of combining drugs for example a myristoyl pocket inhibitor with a traditional inhibitor. So I think that those areas would be very valuable. The introduction of other pathways that could be targeted to help us eliminate the stem cells and improve the ability to get to treatment-free remission. There’s a lot of effort in the treatment-free remission area. With the International CML Foundation, for example, we’re putting a big grant on Cure CML. We’re trying to focus on eliminating the disease and getting there because I think that that’s probably the next big step in really conquering CML. So that is very exciting. It’s challenging. It’s not easy, but I think it’s going to be a very attractive goal. And I think we’re going to get there. We’re just going to take some work.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
